Immunoglobulin light chain amyloidosis: diagnosis and risk assessment

S Zanwar, MA Gertz, E Muchtar - Journal of the National Comprehensive …, 2023 - jnccn.org
Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder with multiple
clinical presentations. The diagnosis of AL amyloidosis requires a high index of suspicion …

Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia

I Dogliotti, C Jiménez, M Varettoni, D Talaulikar… - Leukemia, 2023 - nature.com
The diagnosis of Waldenström's macroglobulinemia (WM), an IgM-associated
lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease …

Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond

S Zanwar, JP Abeykoon - Therapeutic Advances in …, 2022 - journals.sagepub.com
Waldenström macroglobulinemia (WM) is an indolent lymphoplasmacytic lymphoma. Recent
strides made in the genomic profiling of patients with WM have led to the identification of …

IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

S Sidana, DP Larson, PT Greipp, R He, ED McPhail… - Leukemia, 2020 - nature.com
This study evaluates newly diagnosed IgM (6%, n= 75/1174) vs. non-IgM light chain
amyloidosis patients. IgM amyloid patients had lower light chains (12.5 vs. 22.5 mg/dL; p< …

Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement

S Oubari, E Naser, M Papathanasiou… - European Journal of …, 2021 - Wiley Online Library
Objective To study the impact of time to diagnosis on cardiac Mayo stages, treatment
outcome, and overall survival. Methods We retrospectively analyzed 77 consecutive patients …

Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia

S Zanwar, JP Abeykoon, SM Ansell… - British journal of …, 2021 - Wiley Online Library
Patients with asymptomatic/smouldering Waldenström macroglobulinaemia (SWM) have a
variable risk of progression to active WM. Our study evaluated 143 patients with SWM …

Waldenström Macroglobulinemia-A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk …

M Bibas, S Sarosiek, JJ Castillo - Mediterranean Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Waldenström macroglobulinemia (WM) is an infrequent variant of lymphoma, classified as a
B-cell malignancy identified by the presence of IgM paraprotein, infiltration of clonal, small …

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

JN Gustine, RE Szalat, A Staron, T Joshi… - …, 2022 - pmc.ncbi.nlm.nih.gov
Light chain (AL) amyloidosis is an uncommon clinical manifestation of Waldenström
macroglobulinemia (WM), an IgM-secreting lymphoplasmacytic lymphoma characterized by …

Diagnosis and Risk Stratification in Waldenström Macroglobulinemia

S Zanwar, P Kapoor - Journal of the National Comprehensive Cancer …, 2024 - jnccn.org
Waldenström macroglobulinemia (WM) is a B-cell lymphoma characterized by the presence
of bone marrow lymphoplasmacytic infiltration and circulating monoclonal immunoglobulin …

Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia …

G Merlini, S Sarosiek, G Benevolo, X Cao… - Seminars in …, 2023 - Elsevier
Abstract Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström's
Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis …